BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 22-Oct-2018

There will be no price limit on the trading of the shares of the Company today (22.10.2018) following its corporate declaration.

SQURPHARMA 22-Oct-2018

(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 15.72, Consolidated NAV per share of Tk. 78.41 and Consolidated NOCFPS of Tk. 13.57 for the year ended on June 30, 2018 as against Tk. 14.43, Tk. 66.49 and Tk. 12.94 respectively for the same period of the previous year. (end)

SQURPHARMA 22-Oct-2018

The Board of Directors has recommended 36% cash and 7% stock dividend for the year ended on June 30, 2018. The Board has also approved Tk. 200.00 crore for BMRE, Capital Machinery and Lands for future expansion. Date of AGM: 20.12.2018, Time: 10:00 AM, Venue: Samson H Chowdhury Centre Dhaka Club Ltd., Ramna, Dhaka. Record Date: 27.11.2018. (cont.)

SQURPHARMA 08-Oct-2018

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2018 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2018.

SQURPHARMA 30-Apr-2018

(Q3 Un-audited): Consolidated EPS was Tk. 4.04 for January-March 2018 as against Tk. 3.98 for January-March 2017; Consolidated EPS was Tk. 11.99 for July 2017-March 2018 as against Tk. 10.59 for July 2016-March 2017. Consolidated NOCFPS was Tk. 11.26 for July 2017-March 2018 as against Tk. 11.49 for July 2016-March 2017. Consolidated NAV per share was Tk. 74.75 as on March 31, 2018 and Tk. 66.49 as on June 30, 2017.

SQURPHARMA 23-Apr-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2018.

SQURPHARMA 30-Jan-2018

(Q2 Un-audited): Consolidated EPS was Tk. 3.87 for October-December, 2017 as against Tk. 3.33 for October-December, 2016; Consolidated EPS was Tk. 7.95 for July-December, 2017 as against Tk. 6.62 for July-December, 2016. Consolidated NOCFPS was Tk. 8.66 for July-December, 2017 as against Tk. 7.94 for July-December, 2016. Consolidated NAV per share was Tk. 71.31 as on December 31, 2017 and Tk. 66.49 as on June 30, 2017.

SQURPHARMA 24-Jan-2018

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2018 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2017.

SQURPHARMA 14-Jan-2018

The Company has informed that the Cash Dividend for the year ended on June 30, 2017 has been disbursed.

SQURPHARMA 27-Dec-2017

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AAA" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2017, unaudited financials up to September 30, 2017 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

Previous Next page